 |
Celltrion |
[Alpha Biz= Kim Jisun] In a message posted on its official website on Thursday, Celltrion stated, in relation to the Trump administration's tariff policy outlook, "We have already established a system that allows us to respond immediately, regardless of how the policy is implemented."
Celltrion continued, "Recently, U.S. President Trump, in his inaugural speech, mentioned the possibility of imposing tariffs on foreign-produced pharmaceuticals along with key items such as semiconductors and steel." However, the company noted, "As of now, President Trump has not announced specific policy details regarding tariffs on pharmaceuticals, and the actual implementation is still uncertain, requiring further review and policy consideration."
The company also pointed out that "Tariffs on pharmaceuticals could lead to increased drug prices in the U.S., imposing a significant burden on consumers and the healthcare system.
Therefore, it is uncertain whether President Trump will actually pursue this policy." Additionally, Celltrion reminded that "President Trump had consistently pushed for drug price reductions during his first term, and this tariff policy contradicts the direction of his previous policies."
Celltrion explained that since President Trump's election, it has been closely analyzing various scenarios regarding the potential for tariffs.
The company plans, in the short term, to secure sufficient inventory in the U.S. and, in the medium term, to shift its supply strategy toward active pharmaceutical ingredients (APIs), which are less affected by tariffs than finished drugs.
Celltrion has already secured enough stock to meet local demand in the U.S. without additional imports until at least the third quarter of this year. The company is also exploring partnership options with local manufacturers to produce its products in the U.S.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
